search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
64 ANTI-AGEING


Figure 2: Skin barrier molecules and collagen, elastic and hyaluronic acid enzymes by control vs. Adiponin ( FITC green and Rho red staining).


tripeptide. Both tripeptides are involved in skin cell and tissue regeneration like keratinocytes (by Synepin) and fibroblasts (by Sydermin). Antiagin I is a complex of two


tripeptides of Adiponin and Enfibin and Antiagin II is a complex of four tripeptides of Adinponin, Enfibin, Synepin and Syndermin.


Topically applicable, stable, safe and functionally effective Unlike the stem cell growth factors, exosomes and other human tissue derived protein molecules, the tripeptides like Synepin, Sydermin, Adiponin and Enfibin and their complexes are very stable even at 59 degrees Celsius; have less than 500 Daltons of molecular weight, same in size as pharmaceutical ingredients, topically applicable and transdermally permeable by themselves without encapsulation or any separate delivery agent following the 500 Dalton rule; functionally no different to polypeptides; also confirmed as safe in in vitro and in skin tests with no side effects. Each of the 4 tripeptides composing Dr


Hahn anti-ageing tripeptide complex I and II is shown to inhibit the inflammatory cytokines dose-dependently, form a skin


PERSONAL CARE GLOBAL


barrier and protect the skin or proliferate skin cells and tissues like keratinocytes or fibroblasts in in vitro tests. None of the tripeptides have shown any side effects in skin patch tests and clinical studies.


Adipose-derived Adiponectin tripeptide (INCI name: Acetyl Tripeptide-54 Amide) Adiponin (Acetyl Tripeptide-54 Amide), an adiponectin receptor agonist tripeptide, facilitates proliferation of epidermal cells and generation of ceramides, collagens and hyaluronic acid in the dermis. In addition, it helps to increase the production of filaggrin, an essential molecule for the skin barrier function. In in vitro tests of human fibroblast cell


lines (NIH3T3), Acetyl Tripeptide-54 Amide, when treated, increases the skin barrier molecules like filaggrin, loricrin, involucrin and ceramide synthease.3 Acetyl Tripeptide-54 Amide also


improves regeneration of collagen, elastin and hyaluronic acid synthase (HAS2) in in vitro human fibroblast cell line (CCD- 986sk). In the transdermal evaluation test of


moisture loss (TEML) measured by Vapormeter, Acetyl Tripeptide-54 Amide,


when treated, shows an 18.34% decrease of moisture loss rate at 2 weeks and also in the skin flakiness test, when evaluated by Video Microscope and Image Analyzing Program, the decreased rates of flaky skin by 79.25% and 55.76% immediately after and at 2 weeks.


A safety test of ‘Acetyl Tripeptide-54 Amide 5%’ after 24-hour patch on human skin Thirty-four healthy volunteers participated in the 5% Acetyl Tripeptide-54 Amide patch test using Finn Chamber on skin. No skin reaction was noticed as non-irritant with 0.00 % mean score at 30 minutes, 24 hours and 48 hours.


NFkB inhibition tripeptide (INCI name: Acetyl Tripeptide-74 Amide) “A nuclear factor kappa-B inhibitor derived tripeptide inhibit UVB-induced photoaging process.” As published in the Journal of Dermatological Science (JH Hahn et al., 2014) Ultraviolet (UV) irradiation on the skin


induces photoageing which is characterised by keratinocyte hyper-proliferation, generation of coarse wrinkles, worse laxity and roughness. Upon UV irradiation, nuclear factor kappa B (NF-kB) is activated


August 2020


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84